Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Duke Hasson

Orthopaedic Surgery Orange, CA Medical Doctor

NPI 1831489939 CMS profile 4212828

1120 W La Veta Ave Ste 300, Orange, CA 92868

Open in the dashboard

General payments

$18,428

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Duke Hasson of Orange, CA is reported in the CMS Open Payments database as having received $18,428 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,742 12
2024 General $11,152 19
2023 General $1,986 20
2022 General $730 15
2021 General $659 23
2020 General $396 12
2019 General $763 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Duke Hasson
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Duke Hasson were reported at $2,742. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Duke Hasson Orthopaedic Surgery median Middle half National median
2019 $763 $644 $140–$2,844 $163
2020 $396 $312 $75–$1,860 $114
2021 $659 $520 $117–$2,495 $132
2022 $730 $598 $128–$2,731 $149
2023 $1,986 $461 $128–$2,264 $160
2024 $11,152 $497 $134–$2,475 $164
2025 $2,742 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $11,016 14 payments
  2. Stryker Corporation $4,894 62 payments
  3. Saxum Surgical, Inc. $1,444 6 payments
  4. Abbott Laboratories $368 12 payments
  5. Zimmer Biomet Holdings, Inc. $167 3 payments
  6. Intellijoint Surgical Inc. $164 1 payment
  7. Bioventus LLC $94 3 payments
  8. Merz Pharmaceuticals, LLC $40 1 payment
  9. Ethicon US, LLC $38 1 payment
  10. Merz North America, Inc. $27 1 payment
  11. Other $176 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,000 2 payments
  2. Food and Beverage $4,971 109 payments
  3. Travel and Lodging $3,457 4 payments
Products named General payments · program years 2019–2025
  1. MAKO Knees, Hips $3,058 12 payments
  2. MAKO Knees, Hips $468 4 payments
  3. HOFFMANN $367 9 payments
  4. Proclaim IPG $348 11 payments
  5. AXSOS $206 8 payments
  6. MAKO Joint Replacement Hips, Knees $173 1 payment
  7. Intellijoint HIP $164 1 payment
  8. VARIAX $134 5 payments
  9. Taperloc $121 1 payment
  10. Arthrex $95 1 payment
  11. Other $1,338 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

831

Median for Orthopedic Surgery: 203

Drug cost

$6,949

Median for Orthopedic Surgery: $1,433

Branded share of claims

1.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 58 $2,494
Oxycodone Hcl Generic 136 $1,052
Ondansetron Hcl Generic 86 $920
Tramadol Hcl Generic 145 $559
Mupirocin Generic 80 $494
Pantoprazole Sodium Generic 89 $463
Gabapentin Generic 105 $360
Doxycycline Hyclate Generic 28 $211
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $193
Meloxicam Generic 41 $161

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$169,149

Of which drugs: $634

Medicare patients

318

Average age 75

Services billed

8,831

193 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 27%
Diabetes 24%
Osteoporosis 23%
Depression 19%
Atrial fibrillation 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 69 7,561 $634

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record